Social Media Ideas for Bristol Myers Squibb

<![CDATA[Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand St...

Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating Incomes

Bristol Myers unveils data for one of its next-gen blood cancer drugs

Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.

In Alzheimer’s, Bristol Myers sees big promise beyond amyloid

Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.

Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb leans on specialty medicines and a discounted valuation, while Johnson & Johnson boasts industry-leading margins and cash flow.

How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take.

Bristol Myers Squibb has a well-above-market yield of 4.5% and it appears reasonably safe.

BMS layoffs 2026

BMS layoffs 2026 Anonymous (not verified) Thu, 07/09/2026 - 09:10 field_thread_url https://cafepharma.com/boards/threads/bms-layoffs-2026.713612/...

ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study

Bristol Myers Squibb may have gone big in its pursuit of cereblon E3 ligase modulator (CELMoD) drugs, but today the pharma is standing tall.

<![CDATA[Eli Lilly and Abbisko Announce Drug Development Collaboration]]>

BMS layoffs 2026

BMS layoffs 2026 Anonymous (not verified) Wed, 07/08/2026 - 09:09 field_thread_url https://cafepharma.com/boards/threads/bms-layoffs-2026.713612/...

ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice

The first-in-class EGFRxHER3 bispecific ADC that BMS paid $800 million for has shown strong phase 3 results from China that suggest it could put up a fight against blockbuster TROP...

Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks

Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x.

<![CDATA[Novartis to Acquire Myricx Bio for $1.1 Billion]]>

<![CDATA[Parabilis Medicines Raises $670 Million in Initial Public Offering ]]>

Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program

The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Bruk...

BMS SUCKS!!!

BMS SUCKS!!! Anonymous (not verified) Sun, 07/12/2026 - 12:13 field_thread_url https://cafepharma.com/boards/threads/bms-sucks.660695/ b...

<![CDATA[Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio]]>

Beeline ups its Series A round for immune drug work

The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.

<![CDATA[Biogen Enters $1 Billion Agreement to Acquire RayThera Inc. ]]>

Bristol Myers deepens AI investment with Anthropic deal

The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers have used to adopt the technology across many day-to-da...

Agenus surges on study pivot; Apnimed lines up an IPO

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA...

Replimune got another attempt at lead drug after White House intervention: WSJ

<![CDATA[GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc. ]]>